Overview

• Researchers surveyed 411 adults treated for at least three months, with 148 on Ozempic, 217 on Wegovy and 46 on Mounjaro.
• About 21.3% reported heightened sweetness and 22.6% reported stronger saltiness, while bitterness and sourness were largely unchanged.
• Participants noting sweeter or saltier tastes were more likely to report reduced appetite, greater satiety and fewer cravings.
• Wegovy users were most likely to report increased saltiness sensitivity in this sample (26.7% versus 16.2% for Ozempic and 15.2% for Mounjaro).
• The findings, presented at EASD and published in Diabetes, Obesity and Metabolism, show no direct link between taste change and BMI reduction and rely on self-reported, non-causal data.